Latest News and Press Releases

PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...

Philadelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...

David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel, today, March 23rd at 9:00 AM ET Philadelphia, PA, March 23, 2022 (GLOBE NEWSWIRE) --...

– Study did not meet primary endpoint of significant reduction in Emax Drug Liking for ADAIR vs reference dextroamphetamine, although a trend in favor of ADAIR was observed (p=0.16) – All...

Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and...

- Company in ongoing discussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with...

- Topline data for pivotal abuse study of the Company’s lead investigational program ADAIR expected this quarter - Second development program, ADMIR, continues to advance with...

– Live video webcast presentation on Tuesday, January 25th at 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the...

- Survey results reinforce existing literature that immediate-release (IR) amphetamines, such as Adderall®, are the most commonly abused preparation of prescription stimulants - Company’s...

PHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...